In the Phase 3 TRIUMPH-4 trial, 33% of participants on the 12 mg dose reported diarrhea compared to 13.4% on placebo (Wang et al., Syst Rev Meta-Analysis, 2025)
Where were investing our time and capital Supply Change Capitals broader health thesis around personalized solutions that make it easy for people to eat according to their nutrition and dietary needs aligns well with the opportunities arising in GLP-1 companion products
Under the Poverty Guidelines table for your state, find the line that corresponds with the number of people in your household, and multiply it by 2
This means it may affect more than one part of the bodys metabolic system, including appetite control, insulin response, blood sugar balance, and fat metabolism
For complete dosing details, see the tirzepatide dosing guide
Cardiometabolic Markers Secondary endpoints in published trials have included blood pressure, lipid panel, and inflammatory markers, giving researchers additional data points for modeling broader cardiometabolic effects of triple agonism
